Roche Pharmaceutical Development and Sales Overview

Avastin Global sales CHFbn CER growth -29% Regional sales CER growth US -36% 6.0 Europe -51% 5.0 4.0 3.0 2.0 1.0 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 1,652m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing • Japan: Limited decline due to biosimilars with narrow labels International: Biosimilar erosion slowing CER-Constant Exchange Rates Japan -15% International -21% Roche 157

View entire presentation